Vaccination with GM2/KLH-QS-21 does not benefit patients with stage II melanoma, according to a recently published study. Vaccination with GM2/KLH-QS-21 stimulates the production of antibodies to the GM2 ganglioside, which is an antigen expressed by many melanomas. Serological response to GM2 was shown to be a positive prognostic factor in patients with melanoma and was the rationale for this trial.
The idea of treating cancer with a vaccine has been around since the first vaccines against infectious disease were developed. The GM2 ganglioside, an antigen expressed in most melanomas but with limited expression in normal tissues, was thought to offer a suitable target for such therapeutic vaccination. Previous studies had shown that serological response against GM2 was a favorable prognostic factor. The 5-and 10- year survival rates for patients with melanoma having primary tumors with a Breslow thickness greater than 1.5 mm are just of 74% and 61%, respectively, so European Organization for Research and Treatment of Cancer (EORTC) trial 18961 was launched to compare vaccination to observation in these patients.
“These results clearly indicate that we do not fully comprehend the impact, on the whole, of multiple vaccinations. The effects of such vaccinations might well be detrimental, as was clear at the time of the interim analysis that stopped this trial. Now that we have entered a new era in immunotherapy in melanoma with checkpoint inhibitors like anti-CTLA4, and especially with anti-PD1/PDL1, a new opportunity for vaccine development may have arrived,” said study coordinator Professor Alexander M.M. Eggermont of the Institut Gustave Roussy, Villejuif, Paris-Sud, and Université Paris-Sud, Kremlin Bicêtre, France. This trial was conducted by the EORTC and published in the Journal of Clinical Oncology (2013; doi: 10.1200/JCO.2012.47.9303).
In this phase 3 EORTC 18961 trial, 1,314 patients with stage II melanoma (primary melanoma thicker than 1.5 mm, T3-4N0M0; AJCC Stage II) were randomized to either vaccination with GM2-KLH-QS21 (657 patients) or observation (657 patients). The vaccination treatment consisted of subcutaneous injections given once a week during the first month, then once every 3 months for the first 2 years, and once every 6 months during the third year.
Analyses were by intent to treat, and at a median follow-up of 1.8 years the trial was stopped for futility, and patients did not receive further vaccinations. For relapse-free survival, the hazard ratio (HR) was 1.00 (P=0.99). Overall survival was unfavorable for patients in the vaccination arm compared with the observation arm (HR 1.66; P=0.02). Following the independent data-monitoring committee recommendations, all patients in the vaccination arm stopped their treatment.
At final analysis, the median follow-up was 4.2 years. There were 400 relapses, nine deaths without relapse, and a total of 236 deaths. Decreases in both the relapse-free (1.2%) and overall (2.1%) survival rates were observed in the vaccination arm at 4 years. For these two endpoints, the estimated HRs were 1.03 and 1.16, respectively.
Toxicity was acceptable; 4.6% of patients went off study because of toxicity.